Multiple myeloma

被引：726

作者：

Kyle, Robert A. ^{[1
]}

Rajkumar, S. Vincent ^{[1
]}

机构：

[1] Mayo Clin, Div Hematol, Rochester, MN 55905 USA

来源：

BLOOD | 2008年 / 111卷 / 06期

关键词：

D O I：

10.1182/blood-2007-10-078022

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Multiple myeloma is a clonal plasma cell malignancy that accounts for slightly more than 10% of all hematologic cancers. In this paper, we present a historically focused review of the disease, from the description of the first case in 1844 to the present. The evolution of drug therapy and stem-cell transplantation for the treatment of myeloma, as well as the development of new agents, is discussed. We also provide an update on current concepts of diagnosis and therapy, with an emphasis on how treatments have emerged from a historical perspective after certain important discoveries and the results of experimental studies.

引用

页码：2962 / 2972

页数：11

共 104 条

[21] THALIDOMIDE IS AN INHIBITOR OF ANGIOGENESIS [J].

DAMATO, RJ ;

LOUGHNAN, MS ;

FLYNN, E ;

FOLKMAN, J .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (09) :4082-4085

[22] Treatment of plasma cell dyserasias with thalidomide and its derivatives [J].

Dimopoulos, MA ;

Anagnostopoulos, A ;

Weber, D .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (23) :4444-4454

[23] Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma [J].

Dimopoulos, Meletios ;

Spencer, Andrew ;

Attal, Michael ;

Prince, H. Miles ;

Harousseau, Jean-Luc ;

Dmoszynska, Anna ;

San Miguel, Jesus ;

Hellmann, Andrzej ;

Facon, Thierry ;

Foa, Robin ;

Corso, Alessandro ;

Masliak, Zvenyslava ;

Olesnyckyj, Marta ;

Yu, Zhinuan ;

Patin, John ;

Zeldis, Jerome B. ;

Knight, Robert D. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) :2123-2132

[24]

Dispenzieri A, 2007, MAYO CLIN PROC, V82, P323

[25]

DURIE BGM, 1975, CANCER, V36, P842, DOI 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO

[26]

2-U

[27]

EDELMAN GM, 1962, J EXP MED, V116, P207

[28] Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial [J].

Facon, Thierry ;

Mary, Jean Yves ;

Hulin, Cyrille ;

Benbouker, Lofti ;

Attal, Michel ;

Pegourie, Brigitte ;

Renaud, Marc ;

Guillerm, Jean Luc Harousseau Gaelle ;

Ahletaix, Carine ;

Dib, Mamoun ;

Voillat, Laurent ;

Maisonneuve, Herve ;

Troncy, Jacques ;

Dervaux, Weronique ;

Monconduit, Mathieu ;

Martin, Claude ;

Casassus, Philippe ;

Jaubert, Jerome ;

Jardel, Henry ;

Doyen, Chantal ;

Kolb, Brigitte ;

Anglaret, Bruno ;

Grosbois, Bernard ;

Yakoub-Agha, Ibrahim ;

Mathiot, Claire ;

Avet-Loiseau, Herve .

LANCET, 2007, 370 (9594) :1209-1218

[29]

FEFER A, 1986, J NATL CANCER I, V76, P1269

[30] High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial [J].

Fermand, JP ;

Ravaud, P ;

Chevret, S ;

Divine, M ;

Leblond, V ;

Belanger, C ;

Macro, M ;

Pertuiset, E ;

Dreyfus, F ;

Mariette, X ;

Boccacio, C ;

Brouet, JC .

BLOOD, 1998, 92 (09) :3131-3136

← 1 2 3 4 5 6 7 8 9 10 →